Ernexa Therapeutics Inc. (ERNA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Ernexa Therapeutics Inc. (ERNA) closed at USD 2.17 on 2026-10-15, a change of -95.1 % over the past year, with a market capitalization of USD 3.41M.

Ernexa Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Ernexa Therapeutics Inc. key figures

Previous close

USD 2.17 (2026-10-15)

1-year change

-95.1 %

Market cap

USD 3.41M

Enterprise value

USD -1.27M

P/E ratio (trailing)

-0.15

P/E ratio (forward)

-0.22

EPS (trailing)

-13.63

EPS (forward)

-9.60

PEG ratio

n/a

Price to book

0.76

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.43

Employees

5

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Ernexa Therapeutics Inc. and compare it with other stocks.